ARB-1-6

N/A

Report date: 2025/09/26 15:45:40
NME

Base Information

Drug NameARB-1-6
Drug Alias NameARB-1-6PQ-203
ClassificationSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC)
Mechanisms of ActionAnti-SortilinTubulin polymerisation inhibitors
TargetsSortilinTubulin
Therapy Area/IndicationsSolid tumoursTriple Negative Breast NeoplasmsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesProteinQure Inc
China Registration ClassN/A

Develop Information

Active CompaniesProteinQure Inc
Inactive CompaniesPrincess Margaret Cancer Centre
Active IndicationsSolid tumoursTriple Negative Breast NeoplasmsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A